Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:FTLF NASDAQ:SLN NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.90+2.3%$5.02$4.00▼$7.54$335.84M1.351.19 million shs241,422 shsFTLFFitLife Brands$9.69+1.3%$11.91$8.67▼$20.98$90.94M-0.0123,376 shs4,305 shsSLNSilence Therapeutics$6.86-1.3%$6.41$3.56▼$8.40$324.00M1.52316,251 shs4,276 shsSOPHSOPHiA GENETICS$5.53+2.5%$4.84$2.59▼$5.70$377.04M1.01164,178 shs76,763 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-3.99%+5.68%+19.96%+12.48%+9.53%FTLFFitLife Brands+2.69%+3.35%-2.45%-37.76%-39.33%SLNSilence Therapeutics-5.57%-4.92%+24.11%+46.32%+85.63%SOPHSOPHiA GENETICS+7.57%+3.45%+10.20%+12.50%+80.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.90+2.3%$5.02$4.00▼$7.54$335.84M1.351.19 million shs241,422 shsFTLFFitLife Brands$9.69+1.3%$11.91$8.67▼$20.98$90.94M-0.0123,376 shs4,305 shsSLNSilence Therapeutics$6.86-1.3%$6.41$3.56▼$8.40$324.00M1.52316,251 shs4,276 shsSOPHSOPHiA GENETICS$5.53+2.5%$4.84$2.59▼$5.70$377.04M1.01164,178 shs76,763 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-3.99%+5.68%+19.96%+12.48%+9.53%FTLFFitLife Brands+2.69%+3.35%-2.45%-37.76%-39.33%SLNSilence Therapeutics-5.57%-4.92%+24.11%+46.32%+85.63%SOPHSOPHiA GENETICS+7.57%+3.45%+10.20%+12.50%+80.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.60Moderate Buy$19.00221.82% UpsideFTLFFitLife Brands 2.25Hold$21.50121.99% UpsideSLNSilence Therapeutics 2.57Moderate Buy$34.50402.92% UpsideSOPHSOPHiA GENETICS 2.33Hold$7.5035.53% UpsideCurrent Analyst Ratings BreakdownLatest FTLF, SLN, SOPH, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/21/2026SLNSilence Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SOPHSOPHiA GENETICS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.004/7/2026FTLFFitLife Brands Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/2/2026FTLFFitLife Brands Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.003/19/2026ABEOAbeona Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.003/18/2026SLNSilence Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/17/2026ABEOAbeona Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.003/13/2026SLNSilence Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.003/10/2026ABEOAbeona Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$5.82M57.70N/AN/A$2.94 per share2.01FTLFFitLife Brands$81.46M1.12$1.21 per share7.98$4.65 per share2.08SLNSilence Therapeutics$560K578.57N/AN/A$1.32 per share5.20SOPHSOPHiA GENETICS$77.27M4.91N/AN/A$0.67 per share8.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics$71.18M$1.035.7310.73N/AN/A-60.65%-40.78%5/13/2026 (Estimated)FTLFFitLife Brands$6.33M$0.6315.288.14N/A7.77%19.75%9.57%N/ASLNSilence Therapeutics-$88.61M-$1.87N/AN/AN/A-15,851.88%-101.71%-55.53%5/14/2026 (Estimated)SOPHSOPHiA GENETICS-$79M-$0.52N/AN/AN/A-44.48%-62.74%-21.85%N/ALatest FTLF, SLN, SOPH, and ABEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SLNSilence Therapeutics-$0.1850-$0.33-$0.1450-$0.33$1.26 million$0.42 million5/13/2026Q1 2026ABEOAbeona Therapeutics-$0.34N/AN/AN/A$4.57 millionN/A5/5/2026Q1 2026SOPHSOPHiA GENETICS-$0.2325-$0.27-$0.0375-$0.27$20.40 million$21.69 million3/17/2026Q4 2025ABEOAbeona Therapeutics-$0.35-$0.34+$0.01-$0.34$5.65 million$3.00 million3/6/2026Q4 2025SLNSilence Therapeutics-$0.32-$0.25+$0.07-$0.27$2.19 million$0.03 million3/3/2026Q4 2025SOPHSOPHiA GENETICS-$0.20-$0.28-$0.08-$0.28$21.20 million$21.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.056.936.74FTLFFitLife Brands0.881.530.54SLNSilence TherapeuticsN/A8.728.72SOPHSOPHiA GENETICS1.052.061.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%FTLFFitLife Brands2.32%SLNSilence Therapeutics98.73%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%FTLFFitLife Brands61.40%SLNSilence Therapeutics4.10%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9056.88 million52.96 millionOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableSLNSilence Therapeutics10047.23 million45.30 millionNot OptionableSOPHSOPHiA GENETICS52068.49 million65.14 millionNot OptionableFTLF, SLN, SOPH, and ABEO HeadlinesRecent News About These CompaniesSOPHiA GENETICS (NASDAQ:SOPH) Given Buy Rating at BTIG ResearchMay 7 at 4:15 AM | americanbankingnews.comSOPHiA GENETICS (NASDAQ:SOPH) Earns Buy Rating from BTIG ResearchMay 6 at 8:26 AM | marketbeat.comCritical Comparison: SOPHiA GENETICS (NASDAQ:SOPH) vs. MDxHealth (NASDAQ:MDXH)May 6 at 2:18 AM | americanbankingnews.comSOPHiA Genetics (SOPH) Q1 2026 Earnings TranscriptMay 5 at 8:14 PM | finance.yahoo.comSOPHiA GENETICS Q1 Earnings Call HighlightsMay 5 at 4:19 PM | marketbeat.comSOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call TranscriptMay 5 at 3:05 PM | seekingalpha.comSOPHiA GENETICS (NASDAQ:SOPH) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPSMay 5 at 12:34 PM | marketbeat.comBTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8May 5 at 10:13 AM | finance.yahoo.comSOPHiA GENETICS Reports First Quarter 2026 ResultsMay 5 at 6:45 AM | prnewswire.comSOPHiA GENETICS (SOPH) to Release Earnings on TuesdayMay 3, 2026 | americanbankingnews.comUncovering MTAP deletions in precision oncology researchApril 30, 2026 | labroots.comLSOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,100.00 in StockApril 28, 2026 | marketbeat.comShort Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Drops By 31.0%April 28, 2026 | marketbeat.comSOPHiA GENETICS (SOPH) Projected to Post Earnings on TuesdayApril 28, 2026 | marketbeat.comHow The SOPHiA GENETICS (NasdaqGS:SOPH) Narrative Is Shifting With New Fair Value TargetsApril 26, 2026 | finance.yahoo.comSOPHiA GENETICS SAApril 23, 2026 | edition.cnn.comInsider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells 4,486 Shares of StockApril 21, 2026 | marketbeat.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026April 21, 2026 | prnewswire.comMount Sinai adopts AI platform to advance genomic testingApril 18, 2026 | beckershospitalreview.comBSOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest UpdateApril 17, 2026 | marketbeat.comSOPHiA GENETICS (NASDAQ:SOPH) President Ross Muken Sells 2,800 SharesApril 17, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFTLF, SLN, SOPH, and ABEO Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.90 +0.13 (+2.32%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.FitLife Brands NASDAQ:FTLF$9.68 +0.13 (+1.31%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Silence Therapeutics NASDAQ:SLN$6.86 -0.09 (-1.29%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.SOPHiA GENETICS NASDAQ:SOPH$5.53 +0.13 (+2.48%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
